Efficacy of N-acetyl-cysteine in combination with thiamphenicol in sequential (intramuscular/aerosol) therapy of upper respiratory tract infections even when sustained by bacterial biofilms

被引:11
作者
Macchi, A.
Ardito, F.
Marchese, A.
Schito, G. C.
Fadda, G.
机构
[1] Univ Genoa, Inst Microbiol, I-16132 Genoa, Italy
[2] Univ Cattolica Sacro Cuore, Osped Circolo, Clin Otorinolaringoiatria, Rome, Italy
[3] Univ Cattolica Sacro Cuore, Fdn Macchi Varese, Rome, Italy
[4] Univ Cattolica Sacro Cuore, Inst Microbiol, Rome, Italy
关键词
thiamphenicol glycinate acetylcysteinate; recurrent upper respiratory infections; respiratory pathogens;
D O I
10.1179/joc.2006.18.5.507
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A total of 102 patients with recurrent upper respiratory tract infections underwent microbiological exploration with appropriate sampling and direct biopsies of the infected sites. Therapy was then started and on day 1 each patient received two intramuscular injections of thiamphenicol glycinate acetylcysteinate (TGA). From day 2 to 10 sequential therapy with the same drug was continued employing TGA administered by aerosol. All putative etiologic agents recovered were susceptible to thiamphenicol and only 24 demonstrated the ability to produce in vitro biofilms. The organisms comprised 10 Staphylococcus aureus, 6 Streptococcus pyogenes, 4 Streptococcus pneumoniae and 3 Haemophilus influenzae. Of the 24 subjects in whom biofilms were demonstrated to be present in vivo by Scanning Electron Microscopy, clinical and bacteriological cure was obtained in 21 cases (87.5%) following sequential therapy with TGA. Failures were considered to be persistent signs and symptoms at day 15 after initiation of treatment and lack of eradication of 3 S. aureus strains, despite their in vitro susceptibility to thiamphenicol. Very few adverse events attributable to TGA were reported in this cohort of patients. In no case was discontinuation of treatment deemed necessary by the attending physician.
引用
收藏
页码:507 / 513
页数:7
相关论文
共 38 条
[1]  
Albini E, 1999, ARZNEIMITTEL-FORSCH, V49, P533
[2]   Microbiology of middle meatus in chronic rhinosinusitis [J].
Araujo, E ;
Palombini, BC ;
Cantarelli, V ;
Pereira, A ;
Mariante, A .
AMERICAN JOURNAL OF RHINOLOGY, 2003, 17 (01) :9-15
[3]  
Bozzolasco M., 2002, GIORN ITAL MICROBIOL, VVI, P203
[4]   Anaerobic bacteria in upper respiratory tract and other head and neck infections [J].
Brook, I .
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2002, 111 (05) :430-440
[5]   Anatomical evidence of microbial biofilms in tonsillar tissues - A possible mechanism to explain chronicity [J].
Chole, RA ;
Faddis, BT .
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2003, 129 (06) :634-636
[6]  
Clinical and Laboratory Standards Institute (CSLI), 2005, M100S15 CLSI
[7]  
Costerton W, 2003, J CLIN INVEST, V112, P1466, DOI 10.1172/JCI200320365
[8]   In vitro methods to study staphylococcal biofilm formation [J].
Cramton, SE ;
Gerke, C ;
Götz, F .
MICROBIAL GROWTH IN BIOFILMS, PT A: DEVELOPMENTAL AND MOLECULAR BIOLOGICAL ASPECTS, 2001, 336 :239-255
[9]   Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia [J].
Davis, SL ;
Delgado, G ;
McKinnon, PS .
CLINICAL INFECTIOUS DISEASES, 2005, 41 :S136-S143
[10]   Antioxidant properties of N-acetylcysteine:: their relevance in relation to chronic obstructive pulmonary disease [J].
Dekhuijzen, PNR .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (04) :629-636